|
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation |
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment 2016; 20(35) Authors' objectives Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increasing
disability, reduced quality of life and substantial costs (as a result of both intervention acquisition and
hospitalisation). The objective was to assess the clinical effectiveness and cost-effectiveness of seven
biologic disease-modifying antirheumatic drugs (bDMARDs) compared with each other and conventional
disease-modifying antirheumatic drugs (cDMARDs). The decision problem was divided into those patients
who were cDMARD naive and those who were cDMARD experienced; whether a patient had seve Authors' conclusions bDMARDs appear to have cost per QALY values greater than the thresholds stated by
the National Institute for Health and Care Excellence for interventions to be cost-effective. Future research
priorities include: the evaluation of the long-term HAQ trajectory while on cDMARDs; the relationship
between HAQ direct medical costs; and whether or not bDMARDs could be stopped once a patient has
achieved a stated target (e.g. remission). Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Immunosuppressive Agents; Polyethylene Glycols; Receptors, Tumor Necrosis Factor Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013001081 Date abstract record published 03/01/2014 |
|
|
|